Exhibit 99.1

                USANA Provides Preliminary Fourth Quarter Results

    SALT LAKE CITY--(BUSINESS WIRE)--Jan. 6, 2004--USANA Health
Sciences Inc. (NASDAQ: USNA) announced today the preliminary results
for the fourth quarter of 2003.
    Sales are expected to be approximately $59 million for the quarter
ending Jan. 3, 2004 and will total about $200 million for the fiscal
year. Earnings per share for the fourth quarter are expected to be
approximately $0.32 on a fully diluted basis, of which about $0.02 is
attributable to an adjustment of the company's effective tax rate for
2003. Earnings per share for the fiscal year ended Jan. 3, 2004 are
expected to be about $0.98. These amounts are adjusted to reflect the
2-for-1 forward split of the company's stock effected in October 2003.
    Commenting on the fourth quarter, Gilbert A. Fuller, USANA's chief
financial officer, said, "We are expecting to achieve record sales and
earnings in the fourth quarter and we are very pleased with these
results. Our expected fourth quarter sales growth of more than 50
percent is driven by continued growth in the number of active
Associates in both domestic and international markets. Our expected
earnings per share growth of more than 100 percent illustrates
efficiencies generated by our operations. USANA's commitment to
producing the highest quality, scientifically proven nutritional
supplements that are safe and effective continues to create strong
market response and fuel our optimism about the future."
    USANA plans to announce its final fourth quarter and year-end
results on Feb. 3, 2004; executives will hold a conference call with
investors on Feb. 4, 2004.
    USANA develops and manufactures high-quality nutritionals,
personal care, and weight management products that are sold directly
to Preferred Customers and Associates throughout the United States,
Canada, Australia, New Zealand, Hong Kong, Japan, Taiwan, South Korea,
Singapore and the United Kingdom. More information on USANA can be
found at http://www.usanahealthsciences.com.

    This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act and Section 21E of the
Securities Exchange Act. Actual results could differ materially from
those projected in the forward-looking statements, which involve a
number of risks and uncertainties, including reliance upon the
company's independent Associate network, government regulation of
products, manufacturing and marketing, the possible continued spread
of severe acute respiratory syndrome (SARS) in Asia, and risks
associated with international expansion. The contents of this release
should be considered in conjunction with the warnings and cautionary
statements contained in USANA's most recent filings with the
Securities and Exchange Commission on Forms 10-Q and 10-K.


    CONTACT: USANA Health Sciences Inc., Salt Lake City
             Riley Timmer, 801-954-7100
             investor.relations@us.usana.com